STRO

Sutro Biopharma Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 0/10
Sutro Biopharma sales and earnings growth
STRO Growth
Neutral
  • Revenue Y/Y↓ -24.18%
  • EPS Y/Y↑ 44.46%
  • FCF Y/Y↑ 23.36%
Sutro Biopharma gross and profit margin trends
STRO Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -154.20%
  • ROIC 5Y↓ -98.14%
Sutro Biopharma net debt vs free cash flow
STRO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -285.8

Sutro Biopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks